Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
Recap by typeshit. Post by Semafor on X.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Social media promoters claim peptides speed healing, smooth skin and extend life, and CBS notes the HHS Secretary counts himself a fan.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
GEN ranks the best-selling drugs by 2025 sales, and Lilly's weight loss shot outpaced names like Merck's Keytruda on growth.
Loading…